VIZIMPRO is a drug used to treat patients with a type of lung cancer called advanced non-small cell lung cancer (NSCLC). It is to be used as a first treatment in patients whose cancer has spread to other parts of the body (metastatic) and has certain types of gene mutation.VIZIMPRO is a tablet taken by mouth once a day.
HOW TO USE THIS SNAPSHOT The information provided in Snapshots highlights who participated in the clinical trials that supported the FDA approval of this drug, and whether there were differences among sex, race and age groups. The “MORE INFO” bar shows more detailed, technical content for each section. The Snapshot is intended as one tool for consumers to use when discussing the risks and benefits of the drugs.
LIMITATIONS OF THIS SNAPSHOT: Do not rely on Snapshots to make decisions regarding medical care. Always speak to your health provider about the risks and benefits of a drug. Refer to the VIZIMPRO Prescribing Information for complete information.
VIZIMPRO (dacomitinib) vih-ZIM-pro Pfizer Approval date: September 27, 2018
DRUG TRIALS SNAPSHOT SUMMARY:
What is the drug for?
VIZIMPRO is a drug used to treat patients with a type of lung cancer called advanced non-small cell lung cancer (NSCLC). It is to be used as a first treatment in patients whose cancer has spread to other parts of the body (metastatic) and has certain types of gene mutation.
How is this drug used?
VIZIMPRO is a tablet taken by mouth once a day.
What are the benefits of this drug?
Patients who were treated with VIZIMPRO lived about 15 months without disease progression in comparison to patients who receved comparator drug gefitinib who lived about 9 months without disease progression.
The benefits and side effects of VIZIMPRO were evaluated in one clinical trial.
Enrolled patients had a type of non-small cell lung cancer (NSCLC) that contains specific epidermal growth factor receptor mutations. Patients either never received any chemotherapy treatment for their cancer or the cancer came back after completion of previous chemotherapy treatment.
Patients were treated with either VIZIMPRO or gefitinib (an approved drug for treatment of NSCLC) until either disease progresion or developmet of intolerable side effects.
The benefit of VIZIMPRO in comparison to gefitinimib was assessed by the length of time that patients lived without disease progression (progression free survival or PFS).
CLINICAL TRIAL: Voluntary research studies conducted in people and designed to answer specific questions about the safety or effectiveness of drugs, vaccines, other therapies, or new ways of using existing treatments. COMPARATOR: A previously available treatment or placebo used in clinical trials that is compared to the actual drug being tested. EFFICACY: How well the drug achieves the desired response when it is taken as described in a controlled clinical setting, such as during a clinical trial. PLACEBO: An inactive substance or “sugar pill” that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo. SUBGROUP: A subset of the population studied in a clinical trial. Demographic subsets include sex, race, and age groups.
ver historia personal en: www.cerasale.com.ar [dado de baja por la Cancillería Argentina por temas políticos, propio de la censura que rige en nuestro medio]//
weblog.maimonides.edu/farmacia/archives/UM_Informe_Autoevaluacion_FyB.pdf - //
weblog.maimonides.edu/farmacia/archives/0216_Admin_FarmEcon.pdf - //
www.proz.com/kudoz/english_to_spanish/art_literary/523942-key_factors.html - 65k - // www.llave.connmed.com.ar/portalnoticias_vernoticia.php?codigonoticia=17715 // www.frusculleda.com.ar/homepage/espanol/activities_teaching.htm // http://www.on24.com.ar/nota.aspx?idNot=36331 ||